Indication
Follicular
20 clinical trials
39 products
4 drugs
Product
REVLIMID®Clinical trial
Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in KoreaStatus: Completed, Estimated PCD: 2023-08-15
Clinical trial
An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)Status: Recruiting, Estimated PCD: 2024-02-29
Product
AbexinostatProduct
TazemetostatClinical trial
A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in JapanStatus: Recruiting, Estimated PCD: 2028-03-31
Product
JCAR017Product
DurvalumabClinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)Status: Completed, Estimated PCD: 2023-02-15
Product
IbrutinibProduct
RelatlimabProduct
CC-99282Product
CC-122Product
CC-220Product
NivolumabClinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-03-06
Clinical trial
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-12-31
Product
FludarabineProduct
ADI-001Product
CyclophosphamideProduct
SEA-CD40Product
PembrolizumabProduct
TAK-659Clinical trial
A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2021-08-03
Product
VenetoclaxProduct
GemcitabineProduct
Nab-paclitaxelClinical trial
A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)Status: Completed, Estimated PCD: 2005-06-01
Product
HSPPC-96Clinical trial
A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2020-08-17
Clinical trial
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2018-06-01
Product
ASN002Clinical trial
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-11-23
Product
GolcadomideDrug
VarlilumabDrug
cyclophosphamideProduct
DoxorubicinDrug
VincristineProduct
PrednisoneProduct
BendamustineClinical trial
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).Status: Active (not recruiting), Estimated PCD: 2023-01-25
Product
R2-MANTProduct
R-MANTClinical trial
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
TriamcinoloneProduct
BexaroteneProduct
Nitrogen MustardClinical trial
A Cancer Research Phase I/ II Trial of ALETA-001 in Participants Who Do Not Achieve or Maintain an Optimal Response to Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-12-01
Product
ALETA-001Clinical trial
Phase II Multicenter Clinical Trial: Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic CountriesStatus: Recruiting, Estimated PCD: 2027-06-01
Product
MosunetuzumabClinical trial
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid CancersStatus: Completed, Estimated PCD: 2023-09-29
Product
VemurafenibProduct
CopanlisibClinical trial
A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or BendamustineStatus: Active (not recruiting), Estimated PCD: 2025-08-25
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-02
Product
TrametinibProduct
DabrafenibDrug
SpartalizumabClinical trial
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
RetifanlimabClinical trial
BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2020-08-22
Product
Vincristine sulfate liposome